Cancer drug study patients tend to be younger than most people with the disease in the general population.
Johnson & Johnson’s blockbuster blood cancer drug Darzalex significantly reduced the risk of disease progression or death in patients who have not been previously treated for multiple myeloma, late-stage study data showed.
Eli Lilly and AstraZeneca discontinued late-stage trials testing their Alzheimer’s treatment, the latest among a slew of drugmakers to stop developing treatments for the memory-robbing disease.
The U.S. government’s healthcare program for the elderly will exhaust its reserves for hospital insurance in 2026, three years earlier than the 2017 forecast, the Social Security and Medicare Boards of Trustees said in a report.
Older men may face a premature death if they spend most of the day sitting around, but it does not require a huge amount of exercise to increase their chances of living longer, a study in the UK suggests.
Socially isolated people may be more likely to develop diabetes than adults with closer ties to family and friends, a recent study suggests.
Johnson & Johnson Innovation kick started 2018 by striking collaborative agreements with 15 different organizations and companies to address areas of high unmet medical need in neuroscience, oncology and other areas.
The DUO study showed statistically significant PFS improvement for duvelisib versus standard of care treatment ofatumumab.
U.S. regulators approved the first digital pill with an embedded sensor to track if patients are taking their medication properly, marking a significant step forward in the convergence of healthcare and technology.
Japanese automakers are looking beyond the industry trend to develop self-driving cars and turning their attention to robots to help keep the country’s rapidly graying society on the move.